Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, and Royalty Pharma plc, a largest buyer of biopharmaceutical royalties and a leading funder of innovation across the ...

The global leukemia therapeutics treatment market has seen considerable growth, progressing from USD 14,504.8 million in 2022 to USD 15,246.7 million in 2023. With a projected compound annual growth ...

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 21.3% during the third quarter, Holdings Channel.com reports. The ...

Noncash Stock Compensation: Estimated $41 million for full-year 2024. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...

Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host disease ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Analysts are estimating that Syndax Pharmaceuticals will report an earnings per share (EPS) of $-1.11. Investors in Syndax Pharmaceuticals are eagerly awaiting the company's announcement, hoping for ...